Long-Term Safety and Efficacy of Eltrombopag for Advanced Myelodysplastic Syndromes or Acute Myeloid Leukemia and Severe Thrombocytopenia: Results of the ASPIRE Extension Study

ASPIRE, a three-part, international, phase 2 trial (ClinicalTrials.gov identifier: NCT01440374), investigated eltrombopag efficacy and safety in patients with advanced myelodysplastic syndrome or acute myeloid leukemia and grade 4 thrombocytopenia (<25 × 10(9) platelets/L). Approximately 30–65% o...

Descripción completa

Detalles Bibliográficos
Autores principales: Mittelman, Moshe, Platzbecker, Uwe, Grosicki, Sebastian, Lawniczek, Tomasz, Zhu, Zewen, Selleslag, Dominik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2023
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10614231/
https://www.ncbi.nlm.nih.gov/pubmed/37231838
http://dx.doi.org/10.1159/000531146

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10614231/
https://www.ncbi.nlm.nih.gov/pubmed/37231838
http://dx.doi.org/10.1159/000531146

Ejemplares similares